LCZ696A
Drug
Novartis Pharma AG
Total Payments
$11,276
Transactions
3
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $11,276 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $11,276 | 3 | 100.0% |
Top Doctors Receiving Payments for LCZ696A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Boston, MA | $11,276 | 3 |
Ad
Manufacturing Companies
- Novartis Pharma AG $11,276
Product Information
- Type Drug
- Total Payments $11,276
- Total Doctors 1
- Transactions 3
About LCZ696A
LCZ696A is a drug associated with $11,276 in payments to 1 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2017. In 2017, $11,276 was paid across 3 transactions to 1 doctors.
The most common payment nature for LCZ696A is "Travel and Lodging" ($11,276, 100.0% of total).